As of 27 January 2026, the HTA Council has completed the evidence appraisal on the assessment of the following drugs for their respective indications, for possible government financing: The HTA Council hereby releases its preliminary recommendation on the said health technologies for stakeholder feedback and comments from 27 January to 10 February 2026. These health technologies were continue reading : HTA Council Preliminary Recommendation on Aflibercept, Ranibizumab, and Dexamethasone Implant for the Treatment of Retinal Diseases
HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)
As of 01 December 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg/10 mg capsule] for adults diagnosed with advanced continue reading : HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)